Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial by Zhengping Li, Zekun Li, Xiaoling Cheng, Heng Zhang, Can Yang, Qian Xu, Zhenping Chen, Yingzi Zhen, Gang Li, Guoqing Liu, Wanru Yao, Min Zhou, Jiao Jin, Jie Huang, Yongjun Fang, Liangzhi Xie, Man-Chiu Poon, Runhui Wu

Get full text